As 2017 comes to an end, Daria Thorp, President and CEO of ACD/Labs, looks back the company's 23 year history, and recounts some of its notable solutions, including ACD/Spectrus, ACD/Name and ACD/Percepta. She also discusses Luminata, ACD/labs' award winning impurity control informatics solution, which was introduced earlier this year.
Andrew Anderson reports on the 2017 AAPS Annual Conference by taking a closer look at his recent byline in Laboratory Equipment. He also introduces Joe DiMartino, ACD/Labs' newly appointed solution manager for Luminata, and previews Joe's recent Q&A with Outsourcing-Pharma.com, which discusses how QbD and impurity control management directly impact process development within pharmaceutical R&D organizations.
Gabriela Cimpan reflects on her career in chromatography with a specific look at the influence of Professor Simion Gorcan of Babes-Bolyai University. As she summarizes "Chromatography, like many other things, can be loved or hated. If you happen to love it maybe, like me, you too can attribute it to an inspiring personality in your life. I was taught a long time ago: 'Put a little passion in everything you do and you will succeed'."
It’s that time of year—the leaves are falling, it’s a little cooler, I can’t decide whether to dress for my morning or evening commute, and we announce the release of a new version of ACD/Labs software—version 2017.1. This annual event is a result of the hard work of many. Most importantly, however, it is the culmination of requests of new functionality and tools by customers and partners.
Join us next week in beautiful Baveno, Italy, for SMASH 2017. This year’s organizing committee took the light-hearted step of naming each session/workshop after the name of a popular song. Staying with this theme, we are organizing our Software Symposium titled “Stairway to Heaven” on Sunday, Sept. 17th, where we intend to present to you all of the very exciting developments in the world of ACD/Labs.
Professor Marcel Jaspars, head of the Marine Biodiscovery Centre at the University of Aberdeen, and leader of the PharmaSea project, is featured in this video outlining his team's research methodologies, and their unexpected discoveries related to the treatment of Epilepsy and Alzheimer’s.
Structural Elucidations of NMR spectra, whether combined with other analytical techniques, or on their own, are akin to the challenges of the most complex cryptic crosswords—maybe the kind you find in the weekend editions of The Guardian, or The Times—but much, much tougher with some clues sometimes missing. At least that’s why I believe some of our internal experts and application scientists like the challenges of solving these “puzzles” on a regular basis.
Andrew Anderson and Graham McGibbon sat down with Jack Rudd, senior editor at Technology Networks, to discuss the issue of data heterogeneity as well as some of the other challenges associated with modern labs and businesses. While there seems to be a general appreciation of the problems related to Big Data, it has become clear that the complications caused by data heterogeneity—or the different types and/or compositions of data—are often overlooked.
The fascinating world of metabolite identification is something I’ve been learning a lot about recently. The process of drug discovery to drug development to meeting regulations, and the complicated (often manual) workflow. My informant is colleague, Richard Lee. An easy-going and friendly guy with a vast resource of information ranging from metabolite research to cheesy chick flicks (don’t tell him I shared the latter). Read on to learn more about his research and what we'll be discussing at ASMS 2017 this week!
If you happen to be at Bio-IT World this year, be sure to stop by booth #423 to meet the ACD/Labs team and learn more about our solutions; including our new impurity profile information management solution Luminata. We’ll be busy with a number of activities in addition to networking with our fellow peers. Read on for an overview of what our team has planned for the show and where you can find us.